Fabio Puglisi, Professor of Medical Oncology and Head of the School of Medical Oncology at the University of Udine, Italy shared a post on LinkedIn:
“Pleased to share this multidisciplinary expert consensus on PIK3CA testing in advanced HR+/HER2- breast cancer, developed through a close collaboration between clinicians, molecular pathologists, and researchers.
This work focuses on a key practical issue in precision oncology: how to integrate PIK3CA testing into real-world clinical decision-making. Tissue remains the reference matrix, liquid biopsy is a valuable alternative in selected settings, and NGS is the preferred platform to detect both canonical and non-canonical variants.
Beyond the technical aspects, this paper reflects the importance of connecting clinical care, tissue-based pathology, and liquid biopsy-driven molecular profiling within a shared framework.”
Title: Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus
Authors: Carmine De Angelis, Dario de Biase, Lorenzo Gerratana, Grazia Arpino, Giampaolo Bianchini, Isabella Castellano, Giuseppe Curigliano, Lucia Del Mastro, Alessandra Fabi, Nicola Fusco, Alessandra Gennari, Valentina Guarneri, Claudio Zamagni, Alberto Zambelli, Umberto Malapelle, Fabio Puglisi
Read The Full Article
Other articles about Breast Cancer on OncoDaily.